Sangamo Therapeutics Reports Officer and Director Changes
Ticker: SGMO · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1001233
| Field | Detail |
|---|---|
| Company | Sangamo Therapeutics, Inc (SGMO) |
| Form Type | 8-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance
Related Tickers: SGMO
TL;DR
Sangamo Therapeutics (SGMO) filed an 8-K detailing changes to its board and executive team effective Sept 9th.
AI Summary
Sangamo Therapeutics, Inc. filed an 8-K on September 11, 2025, reporting changes effective September 9, 2025. The filing pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the changes are outlined within the report.
Why It Matters
Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty about future strategy and execution.
Key Players & Entities
- SANGAMO THERAPEUTICS, INC. (company) — Registrant
- September 9, 2025 (date) — Effective date of reported changes
- September 11, 2025 (date) — Filing date of the 8-K
- 501 Canal Blvd., Richmond, California 94804 (address) — Principal executive offices
FAQ
What specific roles were affected by the changes reported in the 8-K?
The 8-K filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers.
When were these changes effective according to the filing?
The changes reported in the 8-K were effective as of September 9, 2025.
What is the primary business of Sangamo Therapeutics, Inc.?
Sangamo Therapeutics, Inc. is involved in Biological Products (No Diagnostic Substances), with SIC code 2836.
What is the filing date of this 8-K report?
This 8-K report was filed on September 11, 2025.
Where are Sangamo Therapeutics' principal executive offices located?
Sangamo Therapeutics' principal executive offices are located at 501 Canal Blvd., Richmond, California 94804.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2025-09-11 17:00:46
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value per share SGMO Nasdaq Capital
Filing Documents
- sgmo-20250909.htm (8-K) — 28KB
- 0001001233-25-000011.txt ( ) — 140KB
- sgmo-20250909.xsd (EX-101.SCH) — 2KB
- sgmo-20250909_lab.xml (EX-101.LAB) — 21KB
- sgmo-20250909_pre.xml (EX-101.PRE) — 12KB
- sgmo-20250909_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SANGAMO THERAPEUTICS, INC. Dated: September 11, 2025 By: /s/ SCOTT B. WILLOUGHBY Name: Scott B. Willoughby Title: Chief Legal Officer and Corporate Secretary